{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG001","OG002","OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0206","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73.5","upperLimit":"93.1","value":"83.3"},{"groupId":"OG001","lowerLimit":"50.8","upperLimit":"88.4","value":"69.6"},{"groupId":"OG002","lowerLimit":"85.1","upperLimit":"100","value":"93.5"},{"groupId":"OG003","lowerLimit":"48.9","upperLimit":"93.9","value":"71.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"14"}],"units":"Participants"}],"description":"122 participants with a diagnosis of medulloblastoma were grouped by ERBB2 positive/negative assessment and risk group into 4 groups. Progression-free survival was calculated from the date of diagnosis to the date of disease progression/relapse, the date of death, or the date of last contact. The log-rank test was used to compare the PFS distributions of ERBB2 groups.","dispersionType":"95% Confidence Interval","groups":[{"description":"54 participants who were ERBB2 positive and in the average risk group.","id":"OG000","title":"ERBB2 Positive & Average Risk"},{"description":"23 participants who were ERBB2 positive and in the high risk group","id":"OG001","title":"ERBB2 Positive & High Risk"},{"description":"31 participants who were ERBB2 negative and in the average risk group","id":"OG002","title":"ERBB2 Negative & Average Risk"},{"description":"14 participants who were ERBB2 negative and in the high risk group","id":"OG003","title":"ERBB2 Negative & High Risk"}],"paramType":"NUMBER","populationDescription":"Analysis was completed for the first 122 participants with a diagnosis of medulloblastoma and with fresh tissue and ERBB2 protein assessments. Participants with a diagnosis of PNET, PNET variants, or ATRT were not included in this analysis.","reportingStatus":"POSTED","timeFrame":"2 years after tumor cell analysis in 122 participants","title":"Progression-Free Survival (PFS) Compared Between ERBB2 Assessment and Risk Group.","type":"PRIMARY","unitOfMeasure":"probability of PFS at 2 years"}